Get the Stockscreener App
0.9901
0.48%
-0.0048
Pre-market:
1.02
0.0299
+3.02%
Cocrystal Pharma Inc stock is traded at $0.9901, with a volume of 131.37K.
It is down -0.48% in the last 24 hours and down -17.49% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
See More
Previous Close:
$0.9949
Open:
$0.99
24h Volume:
131.37K
Relative Volume:
0.06
Market Cap:
$13.65M
Revenue:
-
Net Income/Loss:
$-8.83M
P/E Ratio:
-1.3541
EPS:
-0.7312
Net Cash Flow:
$-8.01M
1W Performance:
-1.97%
1M Performance:
-17.49%
6M Performance:
-2.93%
1Y Performance:
-35.71%
1-Day Range:
$0.95
$1.02
1-Week Range:
$0.95
$1.075
52-Week Range:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
0.9901 | 13.65M | 0 | -8.83M | -8.01M | -0.7312 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Cocrystal Pharma Appoints New CEO to Lead Transition - The Globe and Mail
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details - Minichart
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package - Investing.com India
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer - Moomoo
Cocrystal Pharma taps longtime biotech exec as its new CEO - The Business Journals
Cocrystal Pharma Inc. (COCP) Q1 2026 Earnings: Wider-than-expected Loss as R&D Pipeline ProgressesEarnings Whisper Number - newsline.com
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan - Stock Titan
Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3 - Stock Titan
Cocrystal Pharma names James Sapirstein as CEO - The Pharma Letter
Cocrystal Pharma Inc. Plans to Appoint James Sapirstein as A Member of the Board of Directors - marketscreener.com
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline - TipRanks
Cocrystal Pharma names James Sapirstein as new CEO By Investing.com - Investing.com South Africa
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - BioSpace
Cocrystal Pharma names James Sapirstein as new CEO - Investing.com
Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Antiviral executive James Sapirstein takes helm at Cocrystal Pharma - Stock Titan
COCP: Presentation Highlights CDI-988 - Zacks Small Cap Research
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Cocrystal Pharma (COCP) proxy details board elections, pay and 2026 votes - Stock Titan
Cocrystal Pharma | 8-K: Current report - Moomoo
Cocrystal Pharma (COCP) Unveils Promising Antiviral Developments - GuruFocus
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity - TipRanks
Cocrystal Pharma discovers new pan-viral inhibitors - BioWorld News
Cocrystal Pharma (NASDAQ: COCP) highlights pan-viral inhibitor data and Phase 1b progress - Stock Titan
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewswire
Deadly cruise ship hantavirus; Cocrystal runs lab tests on pan-viral blockers - Stock Titan
COCP Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Advances PipelineEarnings Revision Upgrade - The Legal Advocate
Cocrystal Pharma Stock Slips: Why COCP’s Norovirus Bet Is Back in Focus - Bez Kabli
Cocrystal (COCP) Q1 2026 Earnings Miss by Significant: Key TakeawaysMargin Compression Risk - Newser
Why Is Cocrystal Pharma, Inc. (COCP) Stock Down Today? - Meyka
Cocrystal Pharma, Inc. 2026 Q1 Financials: Company Overview, Segment Information, and Going Concern Risks - minichart.com.sg
Cocrystal (COCP) Declines -3.57% Amid Market Weakness 2026-05-15Market Neutral Pair - newser.com
Cocrystal Pharma Releases Q1 2026 Financial Results - AlphaStreet
Cocrystal Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cocrystal Pharma, Inc. 1Q 2026: Net loss $(2.30M), No revenue — 10-Q Summary - TradingView
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Cocrystal Pharma, Inc. Quarterly Earnings Report - Stock Titan
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
Number of shareholders of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Number of shareholders of Cocrystal Pharma Inc – LS:A3DWYX - TradingView
What Cocrystal (COCP) is building for next year | Q4 2025: EPS Exceeds ExpectationsSlow Growth - newser.com
Cocrystal Pharma Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
[EFFECT] Cocrystal Pharma, Inc. SEC Filing - Stock Titan
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - The Manila Times
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026 - TipRanks
Cocrystal Pharma (COCP) advances Fast Track CDI-988 in Phase 1b norovirus challenge study - Stock Titan
No approved norovirus drugs; Cocrystal tests oral CDI-988 - Stock Titan
Cocrystal Pharma Presentation at ICAR 2026 Highlights - GlobeNewswire
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):